-The Information
Morphic Presents New Biomarker Data At DDW 2023 Supporting MORF-057 Program In Ulcerative Colitis
Morphic Therapeutic (NASDAQ:MORF) today announced the presentation of new preclinical data in the MORF-057 IBD development program that are consistent with previous findings and add new support to mechanistic